Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 24, Issue 4, 2011, Pages 669-679

  Mateos, Laura ^a   Ismail, Muhammad Al Mustafa ^a   Gil Bea, Francisco Javier ^b   Leoni, Valerio ^a   Winblad, Bengt ^b   Björkhem, Ingemar ^c   Cedazo Mínguez, Angel ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

24 hydroxycholesterol; Angiotensin I II; angiotensinogen; cholesterol; mild cognitive impairment; neurodegeneration

Indexed keywords

24 HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; ANGIOTENSINOGEN; CHOLESTEROL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CIRCULATION; BRAIN RENIN ANGIOTENSIN SYSTEM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; MALE; MILD COGNITIVE IMPAIRMENT; NERVE CELL; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION;

EID: 79953731158     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101512     Document Type: Article

References (50)

1. Cedazo-MinguezA(2007) ApolipoproteinEand Alzheimers disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med 11, 1227-1238.
2. Kivipelto M, Rovio S, Ngandu T, Kareholt I, Eskelinen M, Winblad B, Hachinski V, Cedazo-Minguez A, Soininen H, Tuomilehto J, Nissinen A (2008) Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 12, 2762-2771.
3. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimers disease in later life: longitudinal, population based study. BMJ 322, 1447-1451. (Pubitemid 32575406)
4. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330, 1360.
5. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L (2003) Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 60, 223-228. (Pubitemid 36193966)
6. Grobe JL, Xu D, Sigmund CD (2008) An intracellular reninangiotensin system in neurons: fact, hypothesis, or fantasy. Physiology (Bethesda) 23, 187-193.
7. Kumar A, Rassoli A, Raizada MK (1988) Angiotensinogen gene expression in neuronal and glial cells in primary cultures of rat brain. J Neurosci Res 19, 287-290.
8. von Bohlen und Halbach O, Albrecht D (2006) The CNS renin-angiotensin system. Cell Tissue Res 326, 599-616. (Pubitemid 44435828)
9. Phillips MI, de Oliveira EM (2008) Brain renin angiotensin in disease. J Mol Med 86, 715-722.
10. Arregui A, Perry EK, Rossor M, Tomlinson BE (1982) Angiotensin converting enzyme in Alzheimers disease increased activity in caudate nucleus and cortical areas. J Neurochem 38, 1490-1492. (Pubitemid 12039305)
11. He M, Ohrui T, Maruyama M, Tomita N, Nakayama K, Higuchi M, Furukawa K, Arai H (2006) ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease. Neurology 67, 1309-1310. (Pubitemid 44563857)
12. Kehoe PG, Katzov H, Andreasen N, Gatz M, Wilcock GK, Cairns NJ, Palmgren J, de Faire U, Brookes AJ, Pedersen NL, Blennow K, Prince JA (2004) Common variants of ACE contribute to variable age-at-onset of Alzheimers disease. Hum Genet 114, 478-483. (Pubitemid 38678926)
13. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, Prince JA, Love S, Kehoe PG (2009) Angiotensin-converting enzyme levels and activity in Alzheimers disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 1, 163-177.
14. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Muller-Spahn F (2001) Cortical alterations of angiotensin converting enzyme, angiotensin II andAT1 receptor in Alzheimers dementia. Neurobiol Aging 22, 541-546. (Pubitemid 32607737)
15. Ge J, Barnes NM (1996) Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur J Pharmacol 297, 299-306.
16. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS,Welsh-Bohmer KA, Breitner JC (2006) Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 63, 686-692.
17. Bjorkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 24, 806-815. (Pubitemid 38620856)
18. Sparks DL (2008) The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimers disease: the old, the new and the pilot. J Alzheimers Dis 15, 641-656.
19. Rahman A, Akterin S, Flores-Morales A, Crisby M, Kivipelto M, Schultzberg M, Cedazo-Minguez A (2005) High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett 579, 6411-6416. (Pubitemid 41612160)
20. Mateos L, Akterin S, Gil-Bea FJ, Spulber S, Rahman A, Bjorkhem I, Schultzberg M, Flores-Morales A, Cedazo-Minguez A (2009) Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro. Brain Pathol 19, 69-80.
21. Bjorkhem I, Lutjohann D, Breuer O, Sakinis A,Wennmalm A (1997) Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J BiolChem272, 30178-30184. (Pubitemid 27512218)
22. Bjorkhem I, Cedazo-Minguez A, Leoni V, Meaney S (2009) Oxysterols and neurodegenerative diseases. Mol Aspects Med 30, 171-179.
23. Bjorkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U (2006) Oxysterols and Alzheimers disease. Acta Neurol Scand Suppl 185, 43-49.
24. Heverin M, Meaney S, Lutjohann D, Diczfalusy U, Wahren J, Bjorkhem I (2005) Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 46, 1047-1052.
25. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad B, Bjorkhem I (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimers disease. J Lipid Res 45, 186-193. (Pubitemid 38180529)
26. Bjorkhem I (2009) Are side-chain oxidized oxysterols regulators also in vivo? J Lipid Res 50 Suppl, S213-S218.
27. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment -beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246. (Pubitemid 39222993)
28. Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Bjorkhem I (2004) Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 42, 186-191. (Pubitemid 38401447)
29. Cedazo-Minguez A, Hamker U, Meske V, Veh RW, Hellweg R, Jacobi C, Albert F, Cowburn RF, Ohm TG (2001) Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures. Neuroscience 105, 651-661. (Pubitemid 32769829)
30. Yang G, Gray TS, Sigmund CD, Cassell MD (1999) The angiotensinogen gene is expressed in both astrocytes and neurons in murine central nervous system. Brain Res 817, 123-131. (Pubitemid 29225353)
31. Leoni V, Shafaati M, Salomon A, Kivipelto M, Bjorkhem I, Wahlund LO (2006) Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment? Neurosci Lett 397, 83-87. (Pubitemid 43340464)
32. Ghribi O (2008) Potential mechanisms linking cholesterol to Alzheimers disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimers Dis 15, 673-684.
33. Greenwood CE, Winocur G (2005) High-fat diets, insulin resistance and declining cognitive function. Neurobiol Aging 26 Suppl 1, 42-45.
34. Yehuda S, Rabinovitz S, Mostofsky DI (2005) Mediation of cognitive function by high fat diet following stress and inflammation. Nutr Neurosci 8, 309-315.
35. Jansen PJ, Lutjohann D, Thelen KM, von Bergmann K, van Leuven F, Ramaekers FC, Monique M (2009) Absence of ApoE upregulates murine brain ApoD and ABCA1 levels, but does not affect brain sterol levels, while human ApoE3 and human ApoE4 upregulate brain cholesterol precursor levels. J Alzheimers Dis 18, 319-329.
36. Inaba S, Iwai M, Furuno M, Tomono Y, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M (2009) Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension 53, 356-362.
37. Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H, Mogi M, Higaki J, HoriuchiM(2009) Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke 40, 597-603.
38. Saavedra JM (2005) Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 25, 485-512. (Pubitemid 41199709)
39. Phillips MI (1987) Functions of angiotensin in the central nervous system. Annu Rev Physiol 49, 413-435. (Pubitemid 17053904)
40. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J (2003) Inflammation and angiotensin II. Int J Biochem Cell Biol 35, 881-900. (Pubitemid 36379329)
41. Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R, Bouthillier A, Reudelhuber TL, Prat A (2007) Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 27, 9032-9042. (Pubitemid 47312066)
42. Schelman WR, Andres R, Ferguson P, Orr B, Kang E, Weyhenmeyer JA (2004) Angiotensin II attenuates NMDA receptor-mediated neuronal cell death and prevents the associated reduction in Bcl-2 expression. Brain Res Mol Brain Res 128, 20-29. (Pubitemid 39158877)
43. Qiu C, Winblad B, Fratiglioni L (2005) The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4, 487-499. (Pubitemid 40982459)
44. Birkenhager WH, Forette F, Seux ML,Wang JG, Staessen JA (2001) Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 161, 152-156. (Pubitemid 32102382)
45. Gard PR, Rusted JM (2004) Angiotensin and Alzheimers disease: therapeutic prospects. Expert Rev Neurother 4, 87-96. (Pubitemid 38082127)
46. Nikolova JG, Getova DP, Nikolov FP (2000) Effects of ACEinhibitors on learning and memory processes in rats. Folia Med (Plovdiv) 42, 47-51.
47. Raghavendra V, Chopra K, Kulkarni SK (2001) Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides 35, 65-69. (Pubitemid 32382318)
48. Hamai M, Iwai M, Ide A, Tomochika H, Tomono Y, Mogi M, Horiuchi M (2006) Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology 51, 822-828. (Pubitemid 44376401)
49. Iwai M, Horiuchi M (2009) Devil and angel in the reninangiotensin system:ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 32, 533-536.
50. Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66, 300-305.